Urology Research & Practice

Prognostic Markers and Trials in Penile Cancer


Department of Urology, Christie NHS Foundation Trust, Manchester, UK


Department of Urology, James Cook University Hospital, Middlesbrough, UK


Department of Urology, Frimley Park Hospital, Frimley, UK


Department of Urology, University Hospitals Birmingham, Birmingham, UK

Urol Res Pract 2023; 49: 138-146
DOI: 10.5152/tud.2023.22225
Read: 972 Downloads: 492 Published: 17 May 2023

New tumor biomarkers open the potential for designing personalized therapy for penile squamous cell carcinoma. Despite the initial promising results of some biomarkers, controversy remains due to contradictory studies. Further robust research work is required before incorporating biomarkers in the personalized management of penile cancer. This narrative review aims to highlight some of the most commonly and recently investigated biomarkers of penile cancer and to summarize the ongoing registered clinical trials for the management of penile cancer patients.

Cite this article as: Naushad N, Deb AA, Agag AA, Serag HA, Sangar VK. Prognostic markers and trials in penile cancer. Urol Res Pract. 2023;49(3):138-146.

EISSN 2980-1478